Keyphrases
Clinical Pharmacology
100%
Zafirlukast
100%
Animal Pharmacology
100%
Bronchoconstriction
44%
Leukotriene B4 (LTB4)
22%
Airway
22%
Pulmonary Tissue
22%
Placebo
11%
Lung
11%
Inhalation
11%
Alveolar Macrophages
11%
Tumor Necrosis Factor-α
11%
Eosinophils
11%
Allergen
11%
Airway Hyperresponsiveness
11%
Dose Effect
11%
Asthma Management
11%
Animal Species
11%
Orally Administered
11%
Placebo-controlled Study
11%
Platelet-activating Factor
11%
Bronchial Hyperresponsiveness
11%
Bronchoalveolar Lavage Fluid
11%
Anti-inflammatory Drugs
11%
Inflammatory Changes
11%
Pharmacological Profile
11%
Steady-state Concentration
11%
Oral Administration
11%
Cell Infiltration
11%
Selective Antagonist
11%
Sulfur Dioxide
11%
Asthma Symptoms
11%
Plasma Extravasation
11%
Superoxide Production
11%
Airflow
11%
Peak Plasma Concentration
11%
Segmental Allergen Challenge
11%
Twice-daily Dosing
11%
Macrophage Necrosis
11%
Cysteinyl Leukotriene Receptor 2 (CysLT2R)
11%
Bronchoconstrictor
11%
Bronner
11%
Cold Air
11%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Pharmacology
100%
Zafirlukast
100%
Bronchoconstriction
36%
Allergen
18%
Placebo
9%
Respiratory Tract Allergy
9%
Superoxide
9%
Asthma
9%
Placebo-Controlled Study
9%
Thrombocyte Activating Factor
9%
Antiinflammatory Agent
9%
Tumor Necrosis
9%
Extravasation
9%
Peptidoleukotriene
9%
Sulfur Dioxide
9%
Leukotriene D4
9%
Bronchoconstricting Agent
9%
Bron
9%
Leukotriene Receptor
9%
Medicine and Dentistry
Zafirlukast
100%
Bronchoconstriction
36%
Allergen
18%
Placebo
9%
Alveolar Macrophage
9%
Superoxide
9%
Asthma
9%
Leukotriene
9%
Steady State
9%
Platelet-Activating Factor
9%
Placebo-Controlled Study
9%
Antiinflammatory Agent
9%
Eosinophil
9%
Oral Drug Administration
9%
Cellular Infiltration
9%
Bronchoalveolar Lavage Fluid
9%
Tumor Necrosis
9%
Respiratory Tract Allergy
9%
Plasma Extravasation
9%
Sulfur Dioxide
9%
Peptidoleukotriene
9%
Airflow
9%
Leukotriene Receptor
9%
Bron
9%
Leukotriene D4
9%
Bronchoconstricting Agent
9%